FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
News|Videos|August 14, 2020
CV Health: Risk Prevention, Challenges, Education
A key opinion leader discusses effective CV risk prevention measures, challenges to reducing adverse events, and effective patient education resources.
Advertisement
A key opinion leader discusses effective risk prevention measures and challenges to reducing adverse events. He also considers effective educational resources for self-care.
Advertisement
Related to this article
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.
A Swedish observational study linked NOAC use to slower cognitive decline in individuals with atrial fibrillation and Alzheimer disease.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
Individualizing Obesity Treatment in Primary Care: An Expert Discussion
5